Neuroscience
From The New York Times, concerning glial cell line-derived neurotrophic factor (GDNF):
-
Anthony H. Risser
neuroscience | neuropsychology | brain | parkinson disease
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- Business World: Myriad Genetics, Flurizan (mpc-7869), And Alzheimer Disease
From the AP, via Yahoo! News: Largest-Ever Alzheimer's Drug Trial Begins By PAUL ELIAS, AP Biotechnology Writer Sun Mar 12, 6:58 AM ET SAN FRANCISCO - It's tragedy enough that Pat Williams' mother...
- Parkinson Disease, Creatine, And Minocycline
From an NIH new release: Preliminary Study Shows Creatine and Minocycline May Warrant Further Study In Parkinson’s Disease A National Institutes of Health-sponsored clinical trial with 200 Parkinson's disease patients has shown...
- Business World: Acadia Pharm, Acp-103, & Parkinson Disease
From an AP report posted at Yahoo!: Acadia Pharma Says Drug Study Encouraging Wednesday June 22, 7:44 pm ET Acadia Pharmaceuticals Says Lead Drug Helped Psychosis in Parkinson's Patients; Shares Fall SAN DIEGO (AP) -- Acadia Pharmaceuticals Inc....
- Issues In Clinical Trials: Gdnf And Parkinson Disease
Today's New York Times includes a front-page article about the culture of clinical-trials research: what happens to participant subjects when an experimental drug is pulled from testing and, among other issues, how teasing apart placebo-based from...
Neuroscience
Legal World: Amgen, GDNF Clinical Trial, and Parkinson Disease
From The New York Times, concerning glial cell line-derived neurotrophic factor (GDNF):
Judge Rejects Patients' Suit to Get Test Drug[ ... Read the full article ... ]
By ANDREW POLLACK
The New York Times
Published: June 8, 2005
A federal judge has denied a request by two people with Parkinson's disease that he order Amgen to continue giving them a drug they used in a clinical trial that the company discontinued.
The lawsuit raised questions about the rights of patients in clinical trials. The patients accused Amgen, the world's largest biotechnology company, of treating them as "mere guinea pigs" and argued that the company had a legal and moral obligation to continue the treatment, which they said had eased their symptoms.
But Judge P. Kevin Castel of United States District Court in Manhattan ruled Monday that Amgen was under no contractual obligation to continue supplying the drug. He said that the informed consent forms signed by the patients before participating in the trial explicitly acknowledged Amgen's right to terminate it.
-
Anthony H. Risser
neuroscience | neuropsychology | brain | parkinson disease
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- Business World: Myriad Genetics, Flurizan (mpc-7869), And Alzheimer Disease
From the AP, via Yahoo! News: Largest-Ever Alzheimer's Drug Trial Begins By PAUL ELIAS, AP Biotechnology Writer Sun Mar 12, 6:58 AM ET SAN FRANCISCO - It's tragedy enough that Pat Williams' mother...
- Parkinson Disease, Creatine, And Minocycline
From an NIH new release: Preliminary Study Shows Creatine and Minocycline May Warrant Further Study In Parkinson’s Disease A National Institutes of Health-sponsored clinical trial with 200 Parkinson's disease patients has shown...
- Business World: Acadia Pharm, Acp-103, & Parkinson Disease
From an AP report posted at Yahoo!: Acadia Pharma Says Drug Study Encouraging Wednesday June 22, 7:44 pm ET Acadia Pharmaceuticals Says Lead Drug Helped Psychosis in Parkinson's Patients; Shares Fall SAN DIEGO (AP) -- Acadia Pharmaceuticals Inc....
- Issues In Clinical Trials: Gdnf And Parkinson Disease
Today's New York Times includes a front-page article about the culture of clinical-trials research: what happens to participant subjects when an experimental drug is pulled from testing and, among other issues, how teasing apart placebo-based from...